These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12812006)

  • 1. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole.
    Moore N; Hall G; Sturkenboom M; Mann R; Lagnaoui R; Begaud B
    Pharmacoepidemiol Drug Saf; 2003 Jun; 12(4):271-81. PubMed ID: 12812006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.
    Wilton LV; Heeley EL; Pickering RM; Shakir SA
    J Psychopharmacol; 2001 Jun; 15(2):120-6. PubMed ID: 11448085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sertindole: new drug. Another "atypical" neuroleptic; QT prolongation.
    Prescrire Int; 2007 Apr; 16(88):59-62. PubMed ID: 17458045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dealing with uncertainty in drug safety: lessons for the future from sertindole.
    Waller P
    Pharmacoepidemiol Drug Saf; 2003 Jun; 12(4):283-7; discussion 289-90. PubMed ID: 12812007
    [No Abstract]   [Full Text] [Related]  

  • 5. The European sertindole safety and exposure survey: a follow-up study of 8600 patients.
    Peuskens J; Moore N; Azorin JM; Toumi M; Cochran J
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):804-11. PubMed ID: 17551996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.
    Pezawas L; Quiner S; Moertl D; Tauscher J; Barnas C; Küfferle B; Wolf R; Kasper S
    Int Clin Psychopharmacol; 2000 Jul; 15(4):207-14. PubMed ID: 10954060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment.
    Kasper S; Möller HJ; Hale A
    Eur Arch Psychiatry Clin Neurosci; 2010 Feb; 260(1):59-68. PubMed ID: 19455275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole.
    Lindström E; Farde L; Eberhard J; Haverkamp W
    Int J Neuropsychopharmacol; 2005 Dec; 8(4):615-29. PubMed ID: 15963244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts.
    Thomsen MB; Volders PG; Stengl M; Spätjens RL; Beekman JD; Bischoff U; Kall MA; Frederiksen K; Matz J; Vos MA
    J Pharmacol Exp Ther; 2003 Nov; 307(2):776-84. PubMed ID: 12966159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).
    Thomas SH; Drici MD; Hall GC; Crocq MA; Everitt B; Lader MH; Le Jeunne C; Naber D; Priori S; Sturkenboom M; Thibaut F; Peuskens J; Mittoux A; Tanghøj P; Toumi M; Moore ND; Mann RD
    Acta Psychiatr Scand; 2010 Nov; 122(5):345-55. PubMed ID: 20384598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sertindole: dilemmas for its use in clinical practice.
    Pae CU
    Expert Opin Drug Saf; 2013 May; 12(3):321-6. PubMed ID: 23432404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
    Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N
    Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the safety and tolerability of sertindole.
    Hale AS
    Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S65-70. PubMed ID: 9690973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription-event monitoring and reporting of adverse drug reactions.
    Heeley E; Riley J; Layton D; Wilton LV; Shakir SA
    Lancet; 2001 Dec; 358(9296):1872-3. PubMed ID: 11741629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe.
    Lançon C; Toumi M; Sapin C; Hansen K
    BMC Psychiatry; 2008 Jul; 8():57. PubMed ID: 18638382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sertindole causes distinct electrocardiographic T-wave morphology changes.
    Nielsen J; Graff C; Hardahl T; Andersen MP; Kristoffersen J; Struijk JJ; Toft E; Meyer JM
    Eur Neuropsychopharmacol; 2009 Oct; 19(10):702-7. PubMed ID: 19457646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sertindole in schizophrenia: a clinical review.
    Zoccali RA; Bruno A; Muscatello MR
    J Clin Psychopharmacol; 2015 Jun; 35(3):286-95. PubMed ID: 25830594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data.
    Layton D; Heeley E; Shakir SA
    J Clin Pharm Ther; 2004 Apr; 29(2):171-81. PubMed ID: 15068407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of sertindole on QTD and TPTE.
    Nielsen J; Andersen MP; Graff C; Kanters JK; Hardahl T; Dybbro J; Struijk JJ; Meyer JM; Toft E
    Acta Psychiatr Scand; 2010 May; 121(5):385-8. PubMed ID: 20085555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug safety and efficacy evaluation of sertindole for schizophrenia.
    Karamatskos E; Lambert M; Mulert C; Naber D
    Expert Opin Drug Saf; 2012 Nov; 11(6):1047-62. PubMed ID: 22992213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.